2019
DOI: 10.7326/m18-1967
|View full text |Cite
|
Sign up to set email alerts
|

External Validation of the MEESSI Acute Heart Failure Risk Score

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
24
0
3

Year Published

2019
2019
2023
2023

Publication Types

Select...
8

Relationship

5
3

Authors

Journals

citations
Cited by 43 publications
(27 citation statements)
references
References 29 publications
0
24
0
3
Order By: Relevance
“…Thirty‐five independent variables were recorded, including demographic data (2), co‐morbidities (13), baseline status (3), triggers of the AHF episode (6), vitals (3) and blood analytical results (6) at ED arrival and severity of the AHF index episode (2) (see online supplementary Table for definitions). The two variables assessing the severity of the FEAHF consisted in: (i) calculation of the MEESSI risk score for every patient, as this risk score has recently been reported to accurately estimate the risk of death during the following 30 days in patients diagnosed with AHF in the ED, and (ii) determination of the need for hospitalisation during the index episode. In addition, AHF‐related treatments provided after FEAHF discharge were recorded: renin–angiotensin system inhibitors (RASI), beta‐blockers, mineralo‐corticosteroid receptor blockers (MCRB), loop and thiazide diuretics and digoxin.…”
Section: Methodsmentioning
confidence: 99%
“…Thirty‐five independent variables were recorded, including demographic data (2), co‐morbidities (13), baseline status (3), triggers of the AHF episode (6), vitals (3) and blood analytical results (6) at ED arrival and severity of the AHF index episode (2) (see online supplementary Table for definitions). The two variables assessing the severity of the FEAHF consisted in: (i) calculation of the MEESSI risk score for every patient, as this risk score has recently been reported to accurately estimate the risk of death during the following 30 days in patients diagnosed with AHF in the ED, and (ii) determination of the need for hospitalisation during the index episode. In addition, AHF‐related treatments provided after FEAHF discharge were recorded: renin–angiotensin system inhibitors (RASI), beta‐blockers, mineralo‐corticosteroid receptor blockers (MCRB), loop and thiazide diuretics and digoxin.…”
Section: Methodsmentioning
confidence: 99%
“…Among the 761 screened citations, 28 studies published over the last 10 years 8,20,24,3559 met the inclusion criteria after full-text review (Figure 1). These 28 studies included 19 different risk models that had been used in AHF patients in the ED setting to predict clinical outcomes (Table 1).…”
Section: Resultsmentioning
confidence: 99%
“…In this sense, CTAS+age+sex had a significantly higher discriminative capacity than CTAS for all the assessed outcomes; 52 MTS and MAT-SET had comparable performance in outcomes prediction; 53 BI-EFFECT was better than EFFECT-HF, and FBI-EFFECT better than both, in predicting 30-day mortality; 35,55 EHMRG was better than EFFECT-HF in predicting seven-day mortality; 54 AHFRS provided clearly better estimations than BWH, ADHERE, GWTG-HS and EAHFE-3D, and was similar to EHMRG in predicting short-term SAE (although no p value for any of these comparisons was provided); 39 EHMRG30-ST had comparable performance in predicting 30-day mortality to EHMRG in predicting seven-day mortality in two studies; 44,56 and MEESSI-AHF was better than EHMRG in predicting 30-day mortality in two studies. 38,41 However, it has to be taken into account that many of these comparisons can be considered ‘unfair’, as they were performed in cohorts used for derivation of one of the compared scales, used outcomes different from those evaluated in original derivation in some of the compared scales, or were run in countries where one of the scales under comparison was derived. Therefore, objective comparisons using independent and new multinational populations are still lacking.…”
Section: Resultsmentioning
confidence: 99%
“…Following the same criteria of the EAHFE cohort, patients with AHF concomitant with ACS was excluded. Complete details of the BASEL V cohort have been described elsewhere 18 . Differences were considered to be statistically significant with a P value < .05, or when the HR excluded the value 1.…”
Section: Methodsmentioning
confidence: 99%